Investor Factsheet

Generate PDF-Version

Bayer is a Life Science company with a more than 150-year history and core competencies in the areas of health care and agriculture. With our innovative products, we are contributing to finding solutions to some of the major challenges of our time. The growing and increasingly aging world population requires improved medical care and an adequate supply of food. Bayer is improving people’s quality of life by preventing, alleviating and treating diseases. And we are helping to provide a reliable supply of high-quality food, feed and plant-based raw materials.

We develop new molecules for use in innovative products and solutions to improve the health of humans, animals and plants. Our research and development activities are based on a profound understanding of the biochemical processes in living organisms.

Our goal is to achieve and sustain leadership positions in our markets, thus creating value for our customers, stockholders and employees. To this end, our strategy is designed to help solve some of the most pressing challenges facing humankind, and by doing this exceptionally well we aim to strengthen the company’s earning power.

We are committed to operating sustainably and addressing our social and ethical responsibilities as a corporate citizen, while at the same time respecting the interests of all our stakeholders. Employees with a passion for innovation enjoy excellent development opportunities at Bayer.

All this goes to make up our mission – Bayer: Science For A Better Life.

Published on February 25, 2016 in the Annual Report 2015:

Bayer Group 2014 2015 Change from 2014
€ million € million in %
Sales 41,339 46,324 +12.1
EBIT1 5,395 6,250 +15.8
EBIT before special items2 5,833 7,069 +21.2
EBITDA3 8,315 9,583 +15.2
EBITDA before special items4 8,685 10,266 +18.2
EBITDA margin before special items5 21.0 % 22.2 %
Income before income taxes 4,414 5,245 +18.8
Net income 3,426 4,110 +20.0
Earnings per share (€) from continuing and discontinued operations6 4.14 4.97 +20.0
Core earnings per share (€) from continuing operations7 5.89 6.83 +16.0
Gross cash flow8 6,707 6,999 +4.4
Net cash flow from continuing and discontinued operations9 5,810 6,890 +18.6
Net financial debt 19,612 17,449 -11.0
Capital expenditures as per segment table 2,484 2,556 +2.9
Research and development expenses 3,537 4,281 +21.0
Return on equity 16.8% 17.9%
Equity ratio 28.8% 34.4%

 

 

Bayer AG 2014 2015 Change from 2014
€ million € million in %
Net income 2,454 1,361 -44.5
Allocation to (withdrawal from) retained earnings 593 (706) .
Total dividend payment 1,861 2,067 +11.1
Dividend per share (€) 2.25 2.50 +11.1

 

 

Employees 2014 2015 Change from 2014
in %
Number of employees10 (Dec. 31) 117,400 116,800 -0.5
Personnel expenses (including pension expenses) (€ million) 9,693 11,203 +15,6

 

2014 figures restated; figures for 2011 - 2013 as last reported.
1 EBIT = income after income taxes, plus income taxes, plus financial result. This indicator is not defined in the International Financial Reporting Standards.
2 EBIT before special items = EBIT plus special charges, minus special gains. This indicator is not defined in the International Financial Reporting Standards. See also Combined Management Report, Chapter 14.2 "Calculation of EBIT(DA) Before Special Items.".
3 EBITDA = EBIT plus the amortization of intangible assets and the depreciation of property, plant and equipment, plus impairment losses and minus impairment loss reversals, recognized in profit or loss during the reporting period. This indicator is not defined in the International Financial Reporting Standards. See also Combined Management Report, Chapter 14.2 "Calculation of EBIT(DA) Before Special Items.".
4 EBITDA before special items = EBITDA plus special charges, minus special gains. This indicator is not defined in the International Financial Reporting Standards. See also Combined Management Report, Chapter 14.2 "Calculation of EBIT(DA) Before Special Items.".
5 The EBITDA margin before special items is calculated by dividing EBITDA before special items by sales. This indicator is not defined in the International Financial Reporting Standards. See also Combined Management Report, Chapter 14.2 "Calculation of EBIT(DA) Before Special Items.".
6 Earnings per share as defined in IAS 33 = net income divided by the average number of shares. See also Note [16] to the Consolidated Financial Statements..
7 Core earnings per share = earnings per share, plus / minus amortization and impairment losses / impairment loss reversals of intangible assets, impairment losses / impairment loss reversals on property, plant and equipment, plus special charges, minus special gains (other than amortization and impairment losses / impairment loss reversals), plus / minus the related tax effects and the share of the adjustments attributable to noncontrolling interest. This indicator facilitates the comparability of performance over time. It is not defined in the International Financial Reporting Standards. See also Combined Management Report, Chapter 14.3 "Core Earnings Per Share.".
8 Gross cash flow = income after income taxes, plus income taxes, plus financial result, minus income taxes paid or accrued, plus depreciation, amortization and impairment losses, minus impairment loss reversals, plus / minus changes in pension provisions, minus gains / plus losses on retirements of noncurrent assets, minus gains from the remeasurement of already held assets in step acquisitions. The change in pension provisions includes the elimination of noncash components of EBIT. It also contains benefit payments during the year. Gross cash flow is not defined in the International Financial Reporting Standards. See also Combined Management Report, Chapter 14.5 "Liquidity and Capital Expenditures of the Bayer Group.".
9 Net cash flow = cash flow from operating activities according to IAS 7
10 Full-time equivalents

 

 

With the company’s focus now on the Life Science businesses, a new organizational structure was introduced effective January 1, 2016. The company’s operations are now managed in three divisions – Pharmaceuticals, Consumer Health and Crop Science – and the Animal Health business unit. Bayer currently still owns around 69% of Covestro AG.

2015 Pro Forma Key Data by New Segment

  

Current Events

July 27, 2016

Q2 2016 Interim Report

Add to my calendar
May 2, 2016

Planned dividend payment date

Add to my calendar

 

Current Investor News

Bayer Stock

The capital stock of Bayer AG, amounting to Euro 2,116,986,388.48, is divided into 826,947,808 no-par registered shares.The capital stock underlying the no-par value registered shares is evidenced by permanent global certificates deposited with Clearstream Banking AG, Frankfurt am Main, Germany. The Company’s shareholders have ownership in these certificates in proportion to their respective holdings.The current value of one share - the share price - is determined by the company's total value on the stock market (market capitalization) and the number of shares in circulation.

Security Identification No.
ISINDE000BAY0017
WKNBAY001
CUSIP072730302
Bayer Code
ReutersXetra ®BAYGn.DE
Frankfurter WertpapierbörseBAYGn.F
BloombergXetra ®BAYN GY
Frankfurter WertpapierbörseBAYN GF


Bayer has a significant weighting in virtually all the major stock indices in line with its high market capitalization and share turnover.

Bayer stock is listed on all the German stock exchanges.

Information about the dividend for fiscal 2015


Conforming to the proposal of the Board of Management and the Supervisory Board, the Annual Stockholders’ Meeting on April 29, 2016 passed the resolution to pay a dividend for fiscal 2015 of EUR 2.50 per share.
The resulting payout ratio of 37 percent calculated on core earnings per share is within our target corridor of 30 percent to 40 percent (for details of the calculation of core earnings per share, see Annual Report 2015, Chapter 14.3 of the Combined Management Report).
The dividend yield calculated on the share price of €115.80 at year end 2015 amounts to 2.2 percent and the total dividend payment to €2,067 million.

  

  

Stock ownership by region

Our ownership structure shows the international distribution of our capital stock. The highest proportion of our outstanding shares, almost 28 percent, is held by investors in the United States and Canada, followed by Germany with nearly 21 percent. From a regional perspective, Bayer has a stable ownership structure that has altered only slightly in recent years.

Ownership Structure by Country

 

Credit Rating

Bayer is currently rated as follows: 

Rating agencyLong-term ratingShort-term ratingOutlookLast Update
Standard & Poor'sA-A-2stableJuly 17, 2015
Moody'sA3P-2stableOctober 7, 2015

  

Sales and Earnings Forecast

(published on April 26, 2016 in the Interim Report First Quarter 2016)

Economic Outlook

Based on the business development described in this report and taking into account the potential risks and opportunities as well as the prevailing currency environment, we are confirming the forecast we published in February (see Annual Report 2015, Chapter 18.2).

 

Forward-Looking Statements

This fact sheet may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer’s public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.

Bayer Investor Relations

Building W11
D-51368 Leverkusen
E-Mail: ir@bayer.com
Internet: www.investor.bayer.com

 

Contacts:

Dr. Jürgen Beunink
Phone: +49-214-30-65742
juergen.beunink@bayer.com
Constance Spitzer
Phone: +49-214-30-33021
constance.spitzer@bayer.com
Peter Dahlhoff
Phone: +49-214-30-33022
peter.dahlhoff@bayer.com
Dr. Olaf Weber
Phone: +49-214-30-33567
olaf.weber@bayer.com
Dr. Alexander Rosar
Head of Investor Relations
Phone: +49-214-30-81013
alexander.rosar@bayer.com
Judith Nestmann
Phone: +49-214-30-66836
judith.nestmann@bayer.com

  

Generate PDF-Version

Last updated: February 25, 2016 Copyright © Bayer AG